Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) PT at $13.13

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been given a consensus recommendation of "Buy" by the nine research firms that are covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $13.13.

CMPX has been the subject of several research analyst reports. Wedbush reaffirmed an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. D. Boral Capital restated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Monday, April 28th. Piper Sandler assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price objective for the company. Finally, Leerink Partners upgraded shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd.

Compass Therapeutics Price Performance

Compass Therapeutics stock traded down $0.04 during mid-day trading on Monday, reaching $2.37. 569,493 shares of the company traded hands, compared to its average volume of 953,048. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08. The firm has a market capitalization of $327.73 million, a price-to-earnings ratio of -6.41 and a beta of 1.41. The firm's 50 day moving average price is $2.00 and its 200 day moving average price is $2.20.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). On average, sell-side analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Insider Buying and Selling at Compass Therapeutics

In other Compass Therapeutics news, insider Jonathan Anderman acquired 20,000 shares of the company's stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the insider now directly owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Company insiders own 29.80% of the company's stock.

Institutional Trading of Compass Therapeutics

Several hedge funds have recently modified their holdings of the company. Rhumbline Advisers increased its stake in Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock valued at $187,000 after purchasing an additional 3,822 shares in the last quarter. Invesco Ltd. raised its stake in Compass Therapeutics by 11.3% in the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company's stock worth $57,000 after acquiring an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Compass Therapeutics by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company's stock worth $463,000 after acquiring an additional 5,590 shares during the period. ProShare Advisors LLC grew its stake in Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after purchasing an additional 9,451 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Compass Therapeutics by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock valued at $69,000 after purchasing an additional 11,326 shares during the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.